East Bay Rheumatology Medical Group, INC.

East Bay Rheumatology Medical Group, INC. was paid $16.64M by Medicaid between Jan 2018 and Nov 2024, across 19 billing codes. Its largest line is J0717, Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) — 80% of everything it billed.

Compared with peers

Next to other Specialist providers in California

Rank by total paid#10 of 1,230

Median peer was paid$51K

This provider vs. median324×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	797	$40K
2019	1,689	$1.27M
2020	2,292	$2.05M
2021	3,218	$2.72M
2022	4,477	$3.52M
2023	4,718	$3.30M
2024incomplete	4,988	$3.74M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	80%	4,853	4,318	$13.38M
J0490	Injection, belimumab, 10 mg	6.6%	254	223	$1.10M
J0491	Injection, anifrolumab-fnia, 1 mg	5.2%	203	203	$858K
J1602	Injection, golimumab, 1 mg, for intravenous use	2.5%	217	179	$421K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	1.4%	5,618	5,575	$225K
96401		1.1%	3,689	3,262	$188K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.1%	3,374	3,055	$180K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	<1%	41	36	$110K
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	<1%	1,412	1,398	$66K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	857	854	$58K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	31	26	$30K
99205	Prolong outpt/office vis	<1%	120	118	$9K

7 more codes

99213	Doctor's office visit, returning patient (routine)	<1%	221	$7K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	891	$4K
96415		<1%	284	$3K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	31	$436.14
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	37	$372.75
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)	<1%	13	$252.77
G2012	Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	<1%	33	$76.91

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNEUWELT, CLARK (DOCTOR)